Increased exposure to commercial insights could help the UK military better guide investment in AI for battlefield use. Navigating the AI Landscape: Lessons from the Gartner Hype Cycle for Military ...
Goldman Sachs notes that although the Phase 3 efficacy data for rocatinlimab is less compelling compared to Dupixent, the analyst still sees strong commercial potential for the drug (if approved).